As regulators investigate a potential connection to blood clots, a British trial of the AstraZeneca coronavirus vaccine in children has been halted.
The University of Oxford declared this on Tuesday, leading to the progress of the future.
“While there are no safety issues in pediatric clinical trials,” the University said in a statement. “We will expect further details from the MHRA (UK Regulatory Authority) to review unusual cases of thrombosis/thrombocytopenia in adults prior to further vaccination in this sample.”
The UK Medicines and Healthcare Regulatory Authority (MHRA) is one of several organizations around the world reviewing real-world evidence from the AstraZeneca vaccine launch to decide if there is a definitive correlation between strokes and unusual blood clots following cases first identified in Norway, Europe’s continent.
Read More: British regulator records seven deaths of AstraZeneca blood clot receivers
The MHRA reported over the weekend that there were 30 cases of blood clots, seven fatal, out of 18 million doses given in the UK. The European Medicines Agency said Tuesday that it “has not reached a conclusion and a review is ongoing”.
The department will make a “Wednesday evening” decision and be “near-contacted” with the European Medicines Agency, EU Health Commissioner Stella Kyriakides said later.
The comments were made following the quote from the Italian newspaper Marco Cavaleri, Chief Strategic Vaccine Strategist of the European Medicines Agency, that the “simple” link exists and will be announced by the Agence within hours.
